

Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

HCC1569

RRID:CVCL_1255

Type: Cell Line

Proper Citation

RRID:CVCL_1255

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1255

Proper Citation: RRID:CVCL_1255

Description: Cell line HCC1569 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast ductal carcinoma

Defining Citation: [PMID:9288768](#), [PMID:9833771](#), [PMID:9865903](#), [PMID:11314036](#), [PMID:17157791](#), [PMID:18516279](#), [PMID:19582160](#), [PMID:20164919](#), [PMID:20679594](#), [PMID:22460905](#), [PMID:23151021](#), [PMID:23601657](#), [PMID:24094812](#), [PMID:24176112](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:26759240](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Miscellaneous: Direct author submission of STR profile from Girard, Luc & Gazdar, Adi F., Population: African American., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HCC1569

Synonyms: HCC-1569, Hamon Cancer Center 1569

Cross References: BTO:BTO_0006090, CLO:CLO_0003640, EFO:EFO_0001173, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-157, ArrayExpress:E-TABM-244, ATCC:CRL-2330,

BioSample:SAMN03471817, BioSample:SAMN03473137, BioSample:SAMN10987921, cancercellines:CVCL_1255, Cell_Model_Passport:SIDM00878, ChEMBL-Cells:ChEMBL3308497, ChEMBL-Targets:ChEMBL1075456, CLS:305784, Cosmic:687477, Cosmic:907046, Cosmic:1136354, Cosmic:1176644, Cosmic:1287886, Cosmic:1603204, Cosmic:1935007, Cosmic:1995425, Cosmic:2165006, Cosmic:2787232, Cosmic-CLP:907046, DepMap:ACH-000930, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:907046, GEO:GSM186718, GEO:GSM186719, GEO:GSM217575, GEO:GSM219971, GEO:GSM274679, GEO:GSM344381, GEO:GSM344431, GEO:GSM350503, GEO:GSM481315, GEO:GSM783966, GEO:GSM844545, GEO:GSM847323, GEO:GSM847474, GEO:GSM887041, GEO:GSM888111, GEO:GSM1053726, GEO:GSM1172867, GEO:GSM1172959, GEO:GSM1374501, GEO:GSM1374502, GEO:GSM1401674, GEO:GSM1669848, IARC_TP53:10272, KCLB:71569, KCLB:9S1569, LiGeA:CCLL_878, LINCS_HMS:50210, LINCS_LDP:LCL-1480, PharmacDB:HCC1569_480_2019, PRIDE:PXD030304, Progenetix:CVCL_1255, PubChem_Cell_line:CVCL_1255, SLKBase:3530, Wikidata:Q54881587

ID: CVCL_1255

Record Creation Time: 20220427T220318+0000

Record Last Update: 20260905T180217+0000

Ratings and Alerts

No rating or validation information has been found for HCC1569.

No alerts have been found for HCC1569.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 199 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Perurena N, et al. (2026) EZH2 Inhibitors Sensitize Breast Cancer to HER2 Kinase Inhibitors through Cooperative Effects on YAP and Proapoptotic Regulators. *Cancer research*, 86(6), 1467.

Ochtrop P, et al. (2026) Expanding the payload scope in antibody-drug conjugates by delivery of hydroxy-containing drugs through self-immolative phosphoramidates. *Nature communications*, 17(1), 759.

Guo X, et al. (2026) The WEE1 inhibitor azenosertib broadly enhances efficacy of antibody-drug conjugates with topoisomerase I and microtubule inhibitor payloads. *iScience*, 29(7), 116390.

Pequerul R, et al. (2025) Inter- and intra-tumoral ALDH1 heterogeneity in breast cancer identifies therapeutic opportunities for ALDH1A-specific inhibitors. *Cell chemical biology*.

Mahdi AF, et al. (2025) Pre-Clinical Rationale for Amcenestrant Combinations in HER2+/ER+ Breast Cancer. *International journal of molecular sciences*, 26(2).

Kwiatkowski N, et al. (2025) CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers. *Cell chemical biology*, 32(4), 556.

Michel M, et al. (2025) Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(7), 1275.

Hlavaty SI, et al. (2024) ACS1-dependent acetate utilization rewires mitochondrial metabolism to support AML and melanoma tumor growth and metastasis. *Cell reports*, 43(12), 114988.

Lin CH, et al. (2023) Carboxyl-terminal modulator protein facilitates tumor metastasis in triple-negative breast cancer. *Cancer gene therapy*, 30(3), 404.

Cervia LD, et al. (2023) A Ubiquitination Cascade Regulating the Integrated Stress Response and Survival in Carcinomas. *Cancer discovery*, 13(3), 766.

Stefanski CD, et al. (2023) APC Loss Prevents Doxorubicin-Induced Cell Death by Increasing Drug Efflux and a Chemoresistant Cell Population in Breast Cancer. *International journal of molecular sciences*, 24(8).

Garana BB, et al. (2023) Drug mechanism enrichment analysis improves prioritization of therapeutics for repurposing. *BMC bioinformatics*, 24(1), 215.

Liu Y, et al. (2023) Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial. *Cell research*, 33(5), 389.

Limsakul P, et al. (2023) Transcriptomic Analysis of Subtype-Specific Tyrosine Kinases as Triple Negative Breast Cancer Biomarkers. *Cancers*, 15(2).

Shrestha M, et al. (2023) CDK4/6 inhibitors and the pRB-E2F1 axis suppress PVR and PD-L1 expression in triple-negative breast cancer. *Oncogenesis*, 12(1), 29.

Roelofs PA, et al. (2023) Aberrant APOBEC3B Expression in Breast Cancer Is Linked to Proliferation and Cell Cycle Phase. *Cells*, 12(8).

Han YJ, et al. (2023) An enhancer variant associated with breast cancer susceptibility in Black women regulates TNFSF10 expression and antitumor immunity in triple-negative breast cancer. *Human molecular genetics*, 32(1), 139.

Lee M, et al. (2023) Venadapapirib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety. *Molecular cancer therapeutics*, 22(3), 333.

DiPeri TP, et al. (2023) Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(21), 4385.

Jovanović B, et al. (2023) Heterogeneity and transcriptional drivers of triple-negative breast cancer. *Cell reports*, 42(12), 113564.